CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ASCT0631D | COG | A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors with and without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631 | Pediatric CIRB | Completed |
| ALTE05N1 | COG | Umbrella Long-Term Follow-Up Protocol | Pediatric CIRB | Available to Open |
| ARAR0331 | COG | Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| ACCL2031 | COG | A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors | Pediatric CIRB | Available to Open |
| ARST03P1 | COG | A Pilot Phase II Study for Children with Infantile Fibrosarcoma | Pediatric CIRB | Completed |
| PEPN2113 | COG | A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy | Pediatric CIRB | Available to Open |
| ADVL1522 | COG | A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953; NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor; Rhabdomyosarcoma; Neuroblastoma; Pleuropulmonary Blastoma; Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma | Pediatric CIRB | Completed |
| ADVL1416 | COG | A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS Tumors | Pediatric CIRB | Available to Open |
| AOST1322 | COG | A Phase II Study of Eribulin (IND# 122686; NSC# 707389) in Recurrent or Refractory Osteosarcoma: An Intergroup NCTN Phase II Study | Pediatric CIRB | Completed |
| AOST2031 | COG | A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma | Pediatric CIRB | Available to Open |